Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19

BACKGROUND: Metabolic diseases are risk factors for severe Coronavirus disease (COVID-19), which have a close relationship with metabolic dysfunction-associated fatty liver disease (MAFLD). AIMS: To evaluate the presence of MAFLD and fibrosis in patients with COVID-19 and its association with progno...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Dig Liver Dis
Prif Awduron: Campos-Murguía, Alejandro, Román-Calleja, Berenice Monserrat, Toledo-Coronado, Israel Vicente, González-Regueiro, José Alberto, Solís-Ortega, Alberto Adrián, Kúsulas-Delint, Deyanira, Cruz-Contreras, Mariana, Cruz-Yedra, Nabila, Cubero, Francisco Javier, Nevzorova, Yulia Alexandrowna, Martínez-Cabrera, Carlos Fernando, Moreno-Guillén, Paulina, Lozano-Cruz, Oscar Arturo, Chapa-Ibargüengoitia, Mónica, Gulías-Herrero, Alfonso, Aguilar-Salinas, Carlos Alberto, Ruiz-Margáin, Astrid, Macías-Rodríguez, Ricardo Ulises
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2021
Pynciau:
Liver, Pancreas and Biliary Tract
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047402/
https://ncbi.nlm.nih.gov/pubmed/33551355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dld.2021.01.019
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg